12th mei 2022
Het laatste nieuws
Hier vindt u onze laatste persberichten. Blijf op de hoogte van het laatste nieuws en van de evenementen waar Curium aanwezig is.
3rd mei 2022
Curium’s Phase 3 ECLIPSE Trial Starts Enrolling Patients
19th april 2022
Curium Announces Significant Increase in Detectnet™ (copper Cu 64 dotatate injection) Production Capacity
5th april 2022
Curium Announces FDA Approval of a Generic Version of DaTscan™ (Ioflupane I 123 Injection) in the U.S.
25th januari 2022
Curium to become major player in the supply on non carrier added Lu-177
6th januari 2022
Curium is attending these global congresses in 2022
15th december 2021
Curium is pleased to announce that Sakir Mutevelic MD, MSc has joined as global Chief Medical Officer
27th oktober 2021
Curium Initiates ECLIPSE, a Phase 3 Clinical Trial For Its Investigational Lu 177 PSMA I&T
24th augustus 2021
Curium Announces Submission of an Investigational New Drug (IND) Application for Cu-64 PSMA I&T
1st juni 2021
Curium Acquires Austrian Radiopharmaceuticals Company IASON
5th mei 2021
RadioMedix & Curium Announce Detectnet™ (copper Cu 64 dotatate injection) Inclusion on NCCN Guidelines®
4th mei 2021
Curium Announces Filing of a Generic Version of DaTscan™ (Ioflupane I 123 Injection) in the U.S.
28th april 2021
Curium to Expand Noblesville Facility’s Workforce
23rd maart 2021
RadioMedix & Curium Announce Simplified Coding for Detectnet™ (copper Cu 64 dotatate injection)
17th maart 2021
A statement on the use of Xenon Xe 133 Gas during the COVID-19 pandemic
2nd maart 2021
Eckert & Ziegler’s GalliaPharm® distributed by Curium in France
2nd februari 2021
Curium is attending these global congresses in 2021
26th januari 2021
RadioMedix & Curium Announce Permanent HCPCS Code for Detectnet™ (copper Cu 64 dotatate injection)
9th december 2020
RadioMedix & Curium Announce CMS Transitional Pass-Through Status for Detectnet™ (copper Cu 64 dotatate injection)
8th september 2020